| 18th week of 2010 patent applcation highlights part 60 |
| Patent application number | Title | Published |
|---|
| 20100113320 | Polyaluminum Compostions - A cleaning composition with a limited number of ingredients contains a polyaluminum compound and surfactant. The cleaning composition optionally has an additional amount of fragrance. The cleaning composition optionally has a small amount of solvent. The cleaning composition optionally comprises a group selected from the group consisting of a dye, a builder, a fatty acid, a colorant, a preservative, a chelating agent, a colloidal silica and mixtures thereof. | 2010-05-06 |
| 20100113321 | ACTIVE CONTAINING DELIVERY PARTICLE - The present invention relates to non-surfactant active containing delivery particles, cleaning compositions comprising said particles, and processes for making and using the aforementioned particles and cleaning compositions. When employed in cleaning compositions, such particles provide more uniform active delivery. Thus, resulting in improved cleaning performance without the increased cleaning negatives that may be associated with higher levels of certain active levels. | 2010-05-06 |
| 20100113322 | Azeotrope-Like Compositions Of 1,1,2,3-Tetrachloropropene And Hydrogen Fluoride - An azeotrope-like composition consisting essentially of 1,1,2,3-tetrachloropropene and hydrogen fluoride is provided, as well as methods that involve such an azeotrope-like composition. | 2010-05-06 |
| 20100113323 | Azeotrope-Like Compositions Of 1,1,1,2,3-Pentachloropropane And Hydrogen Fluoride - An azeotrope-like composition consisting essentially of 1,1,1,2,3-pentachloropropane and hydrogen fluoride is provided, as well as methods that involve such an azeotrope-like composition. | 2010-05-06 |
| 20100113324 | SURFACTANT COMPOSITION WITH A REDUCTION OF SURFACE TENSION, INTERFACIAL TENSION, AND CRITICAL MICELLE CONCENTRATION USING A PROTEIN-BASED SURFACTANT SYNERGIST - Surfactant-containing compositions are described which include a protein component that has the effect of improving the surface-active properties of the surfactants contained in the compositions. The surfactant-containing compositions having the protein component demonstrate significantly lower critical micelle concentrations (CMC), reduced surface tensions, and reduced interfacial tensions than do comparable compositions having no protein component. In addition, the surfactant-containing compositions having the protein component has the effect of converting greasy waste contaminants to surface active materials. | 2010-05-06 |
| 20100113325 | COMPOSITION FOR TEXTILE SOFTENER HAVING LOW TEMPERATURE ACTIVITY AND TEXTILE SOFTENER SHEET COMPRISING THE SAME - The present invention relates to a composition for textile softener comprising a cationic surfactant, the ratio of which C7-C21 alkyl substituents analyzed by HLPC (high pressure liquid chromatography) or GC (gas chromatography) is 0.6 or more, as an effective ingredient, and a sheet for textile softener comprising the same. Since the present composition for textile softener has excellent dissolving and dispersing effect even in low temperature water, the sheet comprising this composition is used at a rinse time during washing procedures to represent excellent anti-static effect and textile softening effect to textiles and clothes. | 2010-05-06 |
| 20100113326 | DIMERIC IAP INHIBITORS - Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR | 2010-05-06 |
| 20100113327 | METHODS FOR CONTROLLING MINERALIZATION OF EXTRACELLULAR MATRIX, THERAPEUTIC METHODS BASED THEREON AND MEDICAMENTS FOR USE THEREIN - The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins. | 2010-05-06 |
| 20100113328 | Targeted delivery to legumain-expressing cells - The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells. | 2010-05-06 |
| 20100113329 | Maleamic Acid Polymer Derivatives and Their Bioconjugates - The present invention is directed to maleamic acid derivatives of water soluble polymers, to chemically stable water-soluble polymer succinamic acid-active agent conjugates, and to methods for reproducibly preparing, characterizing and using such polymer reagents and their conjugates. | 2010-05-06 |
| 20100113330 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to methods of using Tetrahydropyrido[4,3-d]Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient. | 2010-05-06 |
| 20100113331 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors - The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes. | 2010-05-06 |
| 20100113332 | METHOD OF TREATING AN INFLAMMATORY DISEASE BY DOUBLE STRANDED RIBONUCLEIC ACID - What is disclosed is the use of a formulation comprising double stranded ribonucleic acid (dsRNA) in the manufacture of a medicament for treating an inflammatory disease in a mammal and inhibiting production of tumor necrosis factor-α (TNF-α) in the mammal. | 2010-05-06 |
| 20100113333 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS - The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis. | 2010-05-06 |
| 20100113334 | METHODS FOR REDUCING OR PREVENTING TRANSMISSION OF NOSOCOMIAL PATHOGENS IN A HEALTH CARE FACILITY - The present invention provides methods and compositions useful for reducing or preventing the transmission of nosocomial pathogens or an epidemic of nosocomial pathogens in a health care facility by decolonizing the gastro-intestinal tract, skin, or nasal passage of carriers and by preventing colonization of individuals at risk who may serve as transmission vehicles or vectors to other individuals. | 2010-05-06 |
| 20100113335 | COMPOSITIONS AND METHODS FOR TREATEMENT OF CANCER - The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. According to an alternative preferred embodiment the use of at least one isolated viral protein or subunit or analog thereof, or an isolated polynucleotide encoding same, is used in the treatment of cancer. | 2010-05-06 |
| 20100113336 | THERAPEUTIC AGENT AND METHOD FOR OVULATION DISORDER CAUSED BY LUTEINIZED UNRUPTURED FOLLICLE - A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle. | 2010-05-06 |
| 20100113337 | METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS - A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage. | 2010-05-06 |
| 20100113338 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISEASE - Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder. | 2010-05-06 |
| 20100113339 | Serum albumin binding proteins with long half-lives - The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. | 2010-05-06 |
| 20100113340 | NUCLEIC ACIDS CODING FOR ADHESION FACTOR OF GROUP B STREPTOCOCCUS, ADHESION FACTORS OF GROUP B STREPTOCOCCUS AND FURTHER USES THEREOF - The present invention is related to nucleic acids coding for adhesion factors of group B | 2010-05-06 |
| 20100113341 | METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE TREATMENT OF CANCER - Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF) for a period of time exceeding 3 days. | 2010-05-06 |
| 20100113342 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE - The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods. | 2010-05-06 |
| 20100113343 | METHODS INVOLVING LEF-1 REGULATION AND USE OF LEF-1 OR COMPOUNDS ALTERING LEF-1 SIGNALLING FOR TREATING OR PREVENTING DISEASES - The present inventions relates to the use of LEF-1 or functional fragments or homologs thereof, or enhancer or inducer of LEF-1 expression, activity or LEF-1 mediated signalling for the preparation of a pharmaceutical for preventing or treating all types of cytopenia of the myeloid or lymphoid lineage. In particular, the present invention relates to the treatment of severe congenital neutropenia. In another embodiment the present invention relates to the treatment of various types of cancer, in particular, of cancer involving altered granulocyte proliferation, survival and differentiation from granulocytes progenitor cells. | 2010-05-06 |
| 20100113344 | Method Of Detection Of Nucleic Acids With A Specific Sequence Composition - This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the use of nucleic acid Target Binding Assemblies to detect and localize specific Target Nucleic Acids. The detection and localization of the Target Nucleic Acid is accomplished even in the presence of nucleic acids which have similar sequences. The method provides for a high degree of amplification of the signal produced by each specific binding event. In particular, methods and compositions are presented for the detection of HIV and HPV nucleic acid in samples. These methods and compositions find use in diagnosis of disease, genetic monitoring, forensics, and analysis of nucleic acid mixtures. Some of the novel compositions used in the detection method are useful in preventing or treating pathogenic conditions. | 2010-05-06 |
| 20100113345 | PREPARATION OF LOW BLEEDING ANTICOAGULANT FUSION PROTEIN AND ITS USE - Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof. | 2010-05-06 |
| 20100113346 | Method of Treating or Preventing Infertility in a Female Mammal and Pharmaceutical Kit for Use in Such Method - The present invention relates to a method of treating infertility in a female mammal that involves controlled ovarian hyperstimulation. The method includes administering to the female a combination of (i) an FSH substance in an amount effective to stimulate follicular development and (ii) a steroid in an effective amount to inhibit or suppress the secretion of luteinising hormone. The steroid can be substances represented by the following formula | 2010-05-06 |
| 20100113347 | EXENATIDE AND DALARGIN-BASED MEDICINAL PREPARATION FOR TREATING PANCREATIC DIABETES - This invention relates to the field of medicine, in particular, to endocrinology. This invention offers a method of potentiation of a therapeutic effect of exenatide by administration of an effective quantity of exenatide in combination with an effective quantity of dalargin. Advantageous therapeutic effects of the invention include lowering of pathologically elevated levels of blood glucose and cholesterol in patients suffering from diabetes mellitus. This invention offers a method of treatment of diabetes mellitus by administration of an effective quantity of exenatide in combination with an effective quantity of dalargin. This invention offers the use of the combination of exenatide and dalargin for the preparation of the medication for the treatment of diabetes mellitus. This invention offers a medicinal preparation for the treatment of diabetes mellitus containing an effective quantity of exenatide, an effective quantity of dalargin and a pharmaceutically acceptable vehicle or diluent, as well as a method of preparation of this preparation. This invention offers a medicinal preparation for the treatment of diabetes mellitus in the form of a kit containing the medicinal preparation exenatide and the medicinal preparation dalargin, as well as a method of use of this medicinal preparation. | 2010-05-06 |
| 20100113348 | PERCUTANEOUSLY ABSORBABLE PREPARATION, PROCESS FOR PRODUCTION THEREOF AND METHOD FOR PERCUTANEOUS ABSORPTION - This invention is to provide a transdermal permeation preparation which includes a concentrated transdermal active ingredient laminate and exhibits high transdermal permeation effect; and a method for producing the preparation | 2010-05-06 |
| 20100113349 | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM STAPHYLOCOCCUS AUREUS - An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of | 2010-05-06 |
| 20100113350 | METHODS AND COMPOSITIONS FOR MODULATING PROSTASIN - The invention provides methods and compositions related to modulating prostasin. | 2010-05-06 |
| 20100113351 | Therapeuting Compositions Comprising an RNAi Agent and a Neurotrophic Factor and Methods of Use Thereof - The invention provides novel combination therapies for treating Huntington's disease which comprise a) BDNF or suitable fragments thereof and b) agents capable of causing inhibition of a gene responsible for the neurodegenerative disease. The invention provides nucleic acid sequences, methods, and systems suitable for applications of these combination therapies. | 2010-05-06 |
| 20100113352 | RETINOL FORMULATIONS AND METHODS FOR THEIR USE - A composition for the treatment of skin comprises a non-emulsified, aqueous suspension of retinol. The composition may further include at least one protein species, and some proteins used in the composition include collagen and elastin. The composition may also include hyaluronic acid. The composition may also include one or more of tocopheryl acetate, propylene glycol, and linseed extract. Also disclosed are methods for making the composition and use of the composition for the treatment of skin. | 2010-05-06 |
| 20100113353 | Method and composition for inhibiting cardiovascular cell proliferation - Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length. | 2010-05-06 |
| 20100113354 | THERAPEUTIC AGENT COMPRISING VASOHIBIN - A therapeutic agent containing Vasohibin for diabetic nephropathy, and a therapeutic agent containing Vasohibin for peritoneal sclerosis. Since the therapeutic agent containing Vasohibin of the present invention is a substance in which Vasohibin inhibits angiogenesis in an autocrine manner, the therapeutic agent is effective for inhibiting the progression of diabetic nephropathy and peritoneal sclerosis in which the inhibition in the angiogenesis or the production of cytokine is important, so that the therapeutic agent is suitably used in, for example, the treatment of a disease requiring an action for inhibiting the progression of diabetic nephropathy, and a disease requiring an inhibitory action for peritoneal sclerosis, or the like. | 2010-05-06 |
| 20100113355 | NOVEL ANTIBODY MOLECULES AND NUCLEIC ACIDS BINDING TO FUNGAL STRESS PROTEIN HSP90 - An scFv peptide comprising a V | 2010-05-06 |
| 20100113356 | CONTROL OF GROWTH AND REPAIR OF GASTRO-INTESTINAL TISSUES BY GASTROKINES AND INHIBITORS - A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers. | 2010-05-06 |
| 20100113357 | Platelet-derived growth factor-responsive neural precursor cells and progeny thereof - This invention provides platelet-derived growth factor-responsive neural precursor (PRP) cells and methods of producing such cells in vivo or in vitro. These cells can further be used to generate neurons, oligodendrocytes and/or astrocytes. | 2010-05-06 |
| 20100113358 | LEPTIN COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE COGNITIVE FUNCTION DISORDERS RESULTING FROM ACCUMULATION OF NEUROFIBRILLARY TANGLES AND AMLYOID BETA - The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of Aβ, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles. | 2010-05-06 |
| 20100113359 | DIMETHYLPHENOXY MODULATORS OF VIRAL PROTEASE ACTIVITY AND/OR PARASITIC ENZYME ACTIVITY - The present invention relates to new dimethylphenoxy inhibitors of viral protease or parasitic enzymes, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-06 |
| 20100113360 | PARATHYROID HORMONE RECEPTOR ACTIVATION AND STEM AND PROGENITOR CELL EXPANSION - The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells. | 2010-05-06 |
| 20100113361 | ANTI-IGE VACCINES - The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs. | 2010-05-06 |
| 20100113362 | METHODS FOR INHIBITING IMMUNE COMPLEX FORMATION IN A SUBJECT - Polypeptides and other compounds that can bind specifically to the C | 2010-05-06 |
| 20100113363 | Use of GLP-1 Peptides - GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety. | 2010-05-06 |
| 20100113364 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2010-05-06 |
| 20100113365 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2010-05-06 |
| 20100113366 | USE OF PROLINE-RICH PEPTIDE DERIVED FROM HYPOTHALAMUS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF CATTLE LEUCOSIS - The invention concerns to the medicinal preparation containing peptides and may be used for the treatment and/or prophylaxis of cattle leucosis. | 2010-05-06 |
| 20100113367 | PEPTIDE-CYTOTOXIC CONJUGATES - The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions. | 2010-05-06 |
| 20100113368 | CHOLESTEROL LOWERING PROTEIN HYDROLYSATES - The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd-, whereby Xaa and Xdd can be His (H), Arg (R) or Lys (K), and Xbb and Xcc can be Pro (P) or Gly (G). | 2010-05-06 |
| 20100113369 | MEANS FOR PREVENTING AND TREATING CELLULAR DEATH AND THEIR BIOLOGICAL APPLICATIONS - Inhibitors for preventing, blacking/silencing caspase-2 activity in cell death. | 2010-05-06 |
| 20100113370 | METHODS AND COMPOUNDS FOR MODULATING INFLAMMATORY PROCESSES - Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the ABCC4-mediated release of leukotrienes, a medicament containing such compound and methods for screening such compounds. | 2010-05-06 |
| 20100113371 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders. | 2010-05-06 |
| 20100113372 | Method For Preparing Kaempferol-3-0-Rutinoside and Composition of Skin External Application Comprising Thereof - Disclosed is a method for the preparation of kaempferol-3-O-rutinoside and a composition of a skin external application comprising kaempferol-3-O-rutinoside as an active ingredient. The method for isolating kaempferol-3-O-rutinoside through hydrolysis uses an enzyme or microbe that removes the sugar selectively from kaempferol-3-O-rutinoside glycosides in a plant extract. Disclosed also is a composition of a skin external application comprising kaempferol-3-O-rutinoside that prevents skin wrinkle. | 2010-05-06 |
| 20100113373 | ANTIVIRAL SUPPLEMENT FORMULATIONS - The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure. | 2010-05-06 |
| 20100113374 | METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of | 2010-05-06 |
| 20100113375 | METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of | 2010-05-06 |
| 20100113376 | PROCESS FOR DOSING SELF-EMULSIFYING DRUG DELIVERY SYSTEMS - The present invention provides process for dosing a self-dispersing drug delivery system comprising an active compound, said process comprising the step of using a dosage dispenser to dose a defined amount of said self-dispersing drug delivery system comprising an active compound and a dosage dispenser containing a self-dispersing drug delivery system comprising an active compound. | 2010-05-06 |
| 20100113377 | Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds - Methods for treating or preventing cardiomyopathy in a subject by administering an al adrenergic receptor agonist, wherein the treatment does not result in increased blood pressure are provided. | 2010-05-06 |
| 20100113378 | Compositions and Methods for Treating and Preventing Cancer Using Analogs of Vitamin D - Disclosed are compositions and methods used to treat and/or prevent cancer and metabolic diseases, such as psoriasis. In one aspect, the present invention pertains to the use of cross-linking analogs of vitamin D and its metabolites employed for the treatment of prostate cancer. | 2010-05-06 |
| 20100113379 | cAMP DEPENDENT INDUCTION OF AUTOPHAGY - The present invention relates to the induction of autophagy via mTOR independent pathways which modulated intracytosolic cAMP levels. In some embodiments, autophagy may be induced in a cell by reducing intracytosolic cAMP levels, for example using a cAMP antagonist, such as clonidine. This may be useful, for example in the treatment of neurodegenerative disorders or pathogen infections. | 2010-05-06 |
| 20100113380 | P2X7 ANTAGONISTS TO TREAT AFFECTIVE DISORDERS - The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X | 2010-05-06 |
| 20100113381 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 2010-05-06 |
| 20100113382 | COMBINED USE OF DIPEPTIDYL PEPTIDASE 4 INHIBITOR AND SWEETENER - The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity. | 2010-05-06 |
| 20100113383 | BIFIDOBACTERIAL GENE SEQUENCES AND THEIR USE - This invention provides nucleic acids and proteins involved in oligosaccharide modification in the species | 2010-05-06 |
| 20100113384 | BACTERIAL ENDOTOXIN FOR THE PREVENTION OF METABOLIC DISORDERS AND BACTERIAL INFECTIONS - The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin. | 2010-05-06 |
| 20100113385 | COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES - The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): | 2010-05-06 |
| 20100113386 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory condition, a reperfusion injury, an ischemic condition, a cardiovascular disease, diabetes, a diabetic complication, cancer, a side effect of cancer chemotherapy, or a radiation-induced injury, and methods for prolonging the half-life of an oxidation-prone compound, comprising administering to a subject in need thereof an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound. | 2010-05-06 |
| 20100113387 | FATTY ACIDS FOR USE AS A MEDICAMENT - The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. | 2010-05-06 |
| 20100113388 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT - An 8-azaprostaglandin represented by formula (I) | 2010-05-06 |
| 20100113389 | METHOD OF TREATING GRAFT-REJECTION USING DEXTRAN SULFATE - The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible. | 2010-05-06 |
| 20100113390 | OLIGOSACCHARIDES DERIVED FROM FUCOIDAN - The present invention provides a fucoidan-derived low molecular weight compound with a good quality of taste, which has a specified structure and function and is free from problems in absorption, antigenicity, uniformity, an anticoagulant activity and so on, which problems arise when developing fucoidan, a sulfated polysaccharide having an extremely large molecular weight, as drugs or health foods. As a result of analyzing low molecular weight compounds obtained by acid hydrolysis of fucoidan, the inventors have identified fucoidan oligosaccharides (I) to (XI). Further, these oligosaccharides have been found to have anti-obesity and/or blood glucose elevation suppressing effects through inhibition of carbohydrate and/or lipid absorption as a result of α-glucosidase inhibition and/or lipase inhibition. | 2010-05-06 |
| 20100113391 | BICYCLIC HETEROCYCLIC COMPOUND | 2010-05-06 |
| 20100113392 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA - The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Bortezomib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic. | 2010-05-06 |
| 20100113393 | Boronic Acid Salts - Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH) | 2010-05-06 |
| 20100113394 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2010-05-06 |
| 20100113395 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 2010-05-06 |
| 20100113396 | Method and Composition for Potentiating an Opiate Analgesic - Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans. | 2010-05-06 |
| 20100113397 | SYNTHESIS OF OSELTAMIVIR CONTAINING PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY - Novel phosphonate compounds are described. The compounds have activity as neuraminidase inhibitors against wild-type and H274Y mutant of H1N1 and H5N1 viruses. The present disclosure also provides an enantioselective synthetic route to known neuraminidase inhibitors oseltamivir and the anti-flu drug Tamiflu®, as well as novel phosphonate compounds, via D-xylose. Another efficient and flexible synthesis of Tamiflu and the highly potent neuraminidase inhibitor Tamiphosphor was also achieved in 11 steps and >20% overall yields from the readily available fermentation product (1S-cis)-3-bromo-3,5-cyclohexadiene-1,2-diol. Most of the reaction intermediates were obtained as crystals without tedious purification procedures. The key transformations include an initial regio- and stereoselective bromoamidation of a bromoarene cis-dihydrodiol, as well as the final palladium-catalyzed carbonylation and phosphonylation. | 2010-05-06 |
| 20100113398 | Treatment and/or Prevention of Non-Viral Epithelial Damage - There is provided the use of an inhibitor of phosphate transporter activity for the manufacture of a medicament for the prevention and/or treatment of non-viral damage to an epithelium, or of a condition caused or characterised by such damage. The inhibitor of phosphate transporter activity may optionally be a phosphono-carboxylic acid, or a pharmaceutically acceptable derivative of such an acid. There are also provided methods of treatment using such inhibitors, acids and derivatives. | 2010-05-06 |
| 20100113399 | Salts and Polymorphs of a Tetracycline Compound - Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general. | 2010-05-06 |
| 20100113400 | 9-Aminomethyl Substituted Minocycline Compounds - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2010-05-06 |
| 20100113401 | METHODS FOR SYNTHESIZING AND PURIFYING AMINOALKYL TETRACYCLINE COMPOUNDS - Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described. | 2010-05-06 |
| 20100113402 | COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 2010-05-06 |
| 20100113403 | COMPOSITIONS CONTAINING COMPOUNDS HAVING STEROID STRUCTURE AND THEIR USE FOR INDUCING THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS OF THE ORGANISM - Use of a mixture of phytosterols, selected from the group comprising: brassicasterol (Delta 5-C22 unsaturated); campesterol; campestanol; stigmasterol (Delta 5-C22 unsaturated); Delta 5-C23-stigmastadienol; clerosterol (Delta 8-C25 unsaturated); Beta-sitosterol; sitostanol; Delta 5-venasterol (Delta 5-C24 unsaturated); Delta 5-C24-stigmastadienol (Delta 5-C24 diene unsaturated); Delta 7-stigmastenol; 24-methylene-cycloartenol; gramisterol; 24-methylcholest-7-enol; isofucosterol; Delta 7-avenasterol (Delta 7-C24 unsaturated); Delta 5-avenastenol, for the manufacture of a medicament to induce into the adult organism proliferation and differentiation of the stem cells which are present in the organism. | 2010-05-06 |
| 20100113404 | ANTI-ANGIOGENIC ACTIVITY OF 2-METHOXYESTRADIOL ANALOGS IN COMBINATION WITH ANTI-CANCER AGENTS - The present invention relates generally to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with anti-cancer agents. More specifically, the present invention relates to methods and compositions for treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol analogs, in combination with anti-cancer agents. | 2010-05-06 |
| 20100113405 | METHYLINDAZOLE MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new methylindazole modulators of 5-HT3 receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-06 |
| 20100113406 | USE OF GLUCOCORTICOIDS FOR TREATMENT OF CONGESTIVE HEART FAILURE - Disclosed are methods comprising administering a dosage form comprising a pharmaceutical carrier and at least one glucocorticoid to a subject suffering from congestive heart failure, wherein the at least one glucocorticoid is present in the dosage form in an amount effective to ameliorate aspects of the congestive heart failure. Also disclosed are related methods and dosage forms. | 2010-05-06 |
| 20100113407 | ANDROGEN TREATMENT IN FEMALES - The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months. | 2010-05-06 |
| 20100113408 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS - A compound having the general formula: | 2010-05-06 |
| 20100113409 | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy) azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide - This invention relates to the hydrochloride salt of 5-[3-{3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or derived form thereof and its use as a medicament. | 2010-05-06 |
| 20100113410 | PYRAZOLOPYRIMIDINE DERIVATIVE - Problem to be Solved To provide a novel compound inhibiting the effect of HSP90, in particular a novel compound inhibiting the function of HSP90 as a chaperone protein and having antitumor activity.
| 2010-05-06 |
| 20100113411 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions - The present invention relates to CGRP antagonists of general formula | 2010-05-06 |
| 20100113412 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to derivatives of imidazo[1,2-a]pyridines of formula I, | 2010-05-06 |
| 20100113413 | MAPK/ERK Kinase Inhibitors - Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: | 2010-05-06 |
| 20100113414 | THIAZOLYL-DIHYDRO-INDAZOLES - The present invention encompasses compounds of the general formula (1) | 2010-05-06 |
| 20100113415 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER - The present invention is directed to compounds of generic formula (I) | 2010-05-06 |
| 20100113416 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES - Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor. | 2010-05-06 |
| 20100113417 | Substituted Spiroamine Compounds - Substituted spiroamine compounds corresponding to the formula (I) | 2010-05-06 |
| 20100113418 | HETEROCYCLIC COMPOUND - The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): | 2010-05-06 |
| 20100113419 | CGRP RECEPTOR ANTAGONISTS - The present invention is directed to compounds of Formula I: | 2010-05-06 |
